Development of radiated immunotoxin anti-cancer drug and IL13-PE38QQR positron tracer
Project/Area Number |
20591498
|
Research Category |
Grant-in-Aid for Scientific Research (C)
|
Allocation Type | Single-year Grants |
Section | 一般 |
Research Field |
Radiation science
|
Research Institution | Yokohama City University |
Principal Investigator |
CHUMPOL Theeraladanon Yokohama City University, 医学研究科, 特任准教授 (20448682)
|
Co-Investigator(Kenkyū-buntansha) |
INOUE Tomio 横浜市立大学, 医学研究科, 教授 (80134295)
康 芸 横浜市立大学, 医学研究科, 特任准教授 (60332607)
|
Project Period (FY) |
2008 – 2010
|
Project Status |
Completed (Fiscal Year 2010)
|
Budget Amount *help |
¥4,550,000 (Direct Cost: ¥3,500,000、Indirect Cost: ¥1,050,000)
Fiscal Year 2010: ¥1,300,000 (Direct Cost: ¥1,000,000、Indirect Cost: ¥300,000)
Fiscal Year 2009: ¥1,300,000 (Direct Cost: ¥1,000,000、Indirect Cost: ¥300,000)
Fiscal Year 2008: ¥1,950,000 (Direct Cost: ¥1,500,000、Indirect Cost: ¥450,000)
|
Keywords | IL-13受容体 / ポジトロン製剤 / 腫瘍イメージング / ^<90>Y標識 / IL-13PE Cytotoxin / イメージング製剤 / 薬剤合成 / DOTA |
Research Abstract |
We performed the basic research in vitro and in vivo experiments with Y-90 labeled IL-13PE Cytotoxin after agreement of material transfer with FDA CBER, and using IL-13 PE Cytotoxin that had been offered from FDA CBER Dr. Puri. Y-90 labeled IL-13PE Cytotoxin is expected the both effect to target IL-13 receptors (IL-13R) for cancer therapy and cellular damage by β-emitter, so Y-90 labeled IL-13PE Cytotoxin is expected for the new radiation anti-cancer Imunotoxin treatment.
|
Report
(4 results)
Research Products
(1 results)